Inventiva (IVA) Shares Outstanding (Diluted Average) (2018 - 2025)
Inventiva (IVA) recorded quarterly Shares Outstanding (Diluted Average) of $217.4 million in Q4 2025, up 11857704.3% quarter-over-quarter from $1833.8 in Q2 2025, and up 240.4% on a YoY basis from $63.9 million in Q4 2024.
Inventiva (IVA) Shares Outstanding (Diluted Average) (2018 - 2025) Analysis & Trends
Inventiva's Shares Outstanding (Diluted Average) history runs 8 years deep, the most recent figure standing at $217.4 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 240.4% year-over-year to $217.4 million; the TTM figure through Dec 2025 stood at $217.4 million (up 240.4% YoY), while the FY2025 annual figure was $217.4 million, up 240.4% from the prior year.
- Shares Outstanding (Diluted Average) was $217.4 million for Q4 2025 at Inventiva, up from $1833.8 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $217.4 million in Q4 2025 to a low of $768.28 in Q2 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $50.6 million across 5 years, with a median of $45.8 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) slumped 100.0% in 2022, then jumped 5959127.8% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $44.8 million in 2021, then fell by 5.62% to $42.3 million in 2022, then advanced by 15.39% to $48.8 million in 2023, then soared by 30.91% to $63.9 million in 2024, then jumped by 240.4% to $217.4 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $217.4 million (Q4 2025), $1833.8 (Q2 2025), and $63.9 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | 217.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 217.45 Mn |
| Jun 30, 2025 | 1,833.77 |
| Dec 31, 2024 | 63.88 Mn |
| Jun 30, 2024 | 1,012.27 |
| Dec 31, 2023 | 48.80 Mn |
| Jun 30, 2023 | 45.78 Mn |
| Dec 31, 2022 | 42.29 Mn |
| Jun 30, 2022 | 768.28 |
| Dec 31, 2021 | 44.81 Mn |
| Jun 30, 2021 | 46.58 Mn |
| Mar 31, 2021 | 46.56 Mn |
| Dec 31, 2020 | 40.39 Mn |
| Jun 30, 2020 | 42.60 Mn |
| Mar 31, 2020 | 32.05 Mn |
| Dec 31, 2019 | 26.03 Mn |
| Dec 31, 2018 | 23.45 Mn |